Schlieren / Zurich, Switzerland, 19 June, 2025 – Memo Therapeutics AG (or "MTx") today announced that its late breaking abstract has been accepted for an oral presentation at the World Transplant Congress ("WTC") in San Francisco taking place 2-6 August 2025. The late breaking oral presentation will include interim results from the Phase II clinical trial evaluating potravitug.

Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or "MTx") has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development.

DIEPENBEEK, Belgium, (May 19, 2025) – Rejuvenate Biomed, an AI-enabled, clinical-stage biotech company developing safe, synergistic combination therapeutics that alter the course of age-related diseases, announced today that the first patient has been dosed in its Phase 2 clinical trial evaluating Rejuvenate Biomed's lead investigational compound, RJx-01, in patients with chronic obstructive pulmonary disease (COPD)-related muscle weakness and sarcopenia.

Amsterdam, the Netherlands, May 07, 2025 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a publication in Nature covering data on the discovery of PLA2G15 as a target for its lead program in neuro- and metabolic diseases. The publication, titled "PLA2G15 is a BMP Hydrolase and its Targeting Ameliorates Lysosomal Disease", is the result of an ongoing collaboration with the team of Dr. Monther Abu-Remaileh at Stanford University.

April 05, 2025 – DEARhealth, pionier in slimme medische software voor zorgverleners en patiënten, heeft zich per 2 april 2025 aangesloten bij Topicus Healthcare. Deze overname markeert een belangrijke mijlpaal in de groei van DEARhealth en biedt nieuwe mogelijkheden om haar innovatieve technologieën verder te ontwikkelen en om de impact op de gezondheidszorg te vergroten.

Munich, Germany and San Francisco, USA, January 09, 2025 – CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry.

Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that Frits van Alphen, MD has been appointed as Chief Development Officer (CDO). He succeeds Dr. Gerald P. Parzmair, who stepped down to pursue other opportunities.

Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the last patient has been enrolled in its 22-site U.S. Phase II trial for its BK polyomavirus ("BKV")-neutralizing antibody, potravitug.

DIEPENBEEK, Belgium, LEICESTER, England, and LOS ANGELES, USA (October 28, 2024) – Rejuvenate Biomed, the University of Leicester, the National Institute for Health and Care Research (NIHR), Leicester Biomedical Research Centre (BRC), and Wellcome Leap Inc. announced today that they have entered into an agreement to execute a Phase 2 clinical trial in patients with chronic obstructive pulmonary disease (COPD)-related sarcopenia.

Hamburg, Germany, October 15th, 2024 – Topas Therapeutics today announced positive topline results from its Phase 2a trial evaluating lead candidate, TPM502, in patients with celiac disease. The study data serves as the first clinical proof of concept for Topas' proprietary nanoparticle platform and its potential to induce targeted, antigen-specific tolerogenic effects.